| 제품명 | Tirzepatide |
|---|---|
| CAS 번호 | 2023788-19-2 |
| 분자식 | C225H348N48O68 |
| 분자량 | 4813.45 g/mol |
| 외관 | 흰색에서 미색의 분말 |
| 순수함 | ≥98% (HPLC) |
| 용해도 | Soluble in water, DMSO, and ethanol |
| 패키지 | 1g, 5g, 10g, 100g, or custom |
도움이 필요하신가요? 저희 팀에 문의해 주세요

Synonyms: Tirzepatide, 2023788-19-2, GIP/GLP-1 receptor agonist, LY3298176, Mounjaro, Zepbound, Glucagon-like peptide-1 receptor agonist
Tirzepatide has been making headlines in the pharmaceutical world as a first-in-class dual agonist targeting both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Originally developed by Eli Lilly and approved for type 2 diabetes under the brand name Mounjaro, it has quickly become a cornerstone in metabolic disease management, with expanding applications in obesity and cardiovascular health. Its unique mechanism not only enhances glycemic control but also delivers superior weight loss outcomes, which has positioned it as one of the most anticipated peptide therapeutics of the decade.
At LyvBio, we supply high-purity Tirzepatide (≥98% by HPLC) in research and development quantities, meeting strict quality criteria. Our product is available as a lyophilized powder, ideal for reconstitution in laboratory settings. Whether you’re conducting preclinical studies, formulation development, or analytical method validation, our Tirzepatide offers reliable performance and comprehensive documentation.
Our product is supplied as a white to off-white powder, freely soluble in water and common organic solvents. Each batch is characterized by mass spectrometry and HPLC to confirm identity and purity, ensuring that researchers receive a consistent and reliable material for their studies.
| 매개변수 | 사양 |
|---|---|
| 분석법 (HPLC) | ≥98.0% |
| 외관 | 흰색에서 미색의 분말 |
| 건조 손실 | ≤5.0% |
| 중금속 | ≤10 ppm |
| Purity (related substances) | Meets internal requirements |